6-ECDCA-d4
(Synonyms: 6α-ethyl Chenodeoxycholic Acid-d4,Obeticholic Acid-d4) 目录号 : GC915646-ECDCA-d4 is intended for use as an internal standard for the quantification of 6-ECDCA by GC- or LC-MS.
Cas No.:2025364-15-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
6-ECDCA-d4 is intended for use as an internal standard for the quantification of 6-ECDCA by GC- or LC-MS. 6-ECDCA is a synthetic bile acid that acts as a potent and selective agonist of the farnesoid X receptor (FXR; EC50 = 99 nM).[1] Through FXR, it alters gene expression that results in protection against cholestasis, as well as liver fibrosis, in animal models.1,2,3 6-ECDCA also, through FXR, promotes the differentiation of adipocytes and enhances insulin signaling in mature adipocytes.[4] In ApoE-/- mice, 6-ECDCA ameliorates vascular calcification secondary to chronic kidney disease without affecting the development of atherosclerosis.[5]
References:
[1].Pellicciari, R., Fiorucci, S., Camaioni, E., et al.6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activityJ. Med. Chem.45(17)3569-3572(2002).
[2].Fiorucci, S., Clerici, C., Antonelli, E., et al.Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasisJ. Pharmacol. Exp. Ther.313(2)604-612(2005).
[3].Fiorucci, S., Rizzo, G., Antonelli, E., et al.A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosisJ. Pharmacol. Exp. Ther.314(2)584-595(2005).
[4].Rizzo, G., Disante, M., Mencarelli, A., et al.The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivoMol. Pharmacol.70(4)1164-1173(2006).
[5].Miyazaki-Anzai, S., Levi, M., Kratzer, A., et al.Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney diseaseCirc. Res.106(12)1807-1817(2010).
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3546 mL | 11.773 mL | 23.546 mL |
| 5 mM | 0.4709 mL | 2.3546 mL | 4.7092 mL |
| 10 mM | 0.2355 mL | 1.1773 mL | 2.3546 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。